BOSTON, MA -- (Marketwired) -- 11/01/16 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, will host a third quarter 2016 investor conference call on Thursday, November 10, 2016 at 10:00 AM (EST) to discuss financial results and provide a corporate update.
To access the call, participants may dial 877-407-8920 (US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call.
An archived replay of the call will be available by dialling 877-660-6853 (US & Canada) or 201-612-7415 (International) and providing the Conference ID #: 13603006.
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin® protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is registered trademarks of Pieris. For more information, visit www.pieris.com. Anticalin®, Anticalins® are registered trademarks of Pieris.
Pieris Pharmaceuticals, Inc.
SVP & Chief Financial Officer
Investor Relations Contact:
The Trout Group
+49 172 861 8540
Source: Pieris Pharmaceuticals, Inc.